Lucentis Effective for Proliferative Diabetic Retinopathy (VIDEO)

NIH/National Eye Institute

Caption

<p>NIH-funded clinical trial marks first major advance in therapy in 40 years. <p>A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (<a target="_blank"href="http://DRCR.net">DRCR.net</a>) compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s.

Credit

National Eye Institute

Usage Restrictions

Courtesy of the National Eye Institute

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.